Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Moon (Guangzhou) Biotechnology probiotic
- Development stage
- Unknown
- Lead developer
- Moon Biotech
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
This probiotic formulation, developed by Moon (Guangzhou) Biotechnology Co., Ltd., is an investigational live biotherapeutic product being evaluated for the treatment of mild-to-moderate anxiety and depression. Administered orally at a dose of 60 billion colony-forming units (CFU) per day, it is designed to modulate the gut-brain axis. In clinical trials, it is being studied as an adjunctive treatment alongside the selective serotonin reuptake inhibitor (SSRI) escitalopram to determine its impact on clinical symptoms (anxiety, depression, and sleep quality) and its ability to alter gut microbiota composition and metabolic profiles. The research aims to elucidate the underlying mechanisms of the probiotic's effect on mental health through the analysis of serum biomarkers and gut-derived metabolites.
- Other names
- Probiotic
02
Targets
STING (Stimulator of interferon genes protein)
Beyond the preview
Go deeper on Moon (Guangzhou) Biotechnology probiotic.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Moon (Guangzhou) Biotechnology probiotic.